The exosomes market in the UK is expected to reach a projected revenue of US$ 42.3 million by 2030. A compound annual growth rate of 30.8% is expected of the UK exosomes market from 2025 to 2030.
In terms of revenue, UK accounted for 4.9% of the global exosomes market in 2024.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
In Europe, Germany exosomes market is projected to lead the regional market in terms of revenue in 2030.
UK is the fastest growing regional market in Europe and is projected to reach USD 42.3 million by 2030.
In 2016, UK ranked the fifth largest global economy by GDP followed by Germany despite its exit from the EU. EvOx, a spin off from the University of Oxford, is involved in the development of a novel drug delivery method using exosomes.
Innovate UK granted USD 2.27 to Re Neuron Group plc to continue the development of its nanomedicine platform using exosomes. Collaborations among emerging players and research institutes is another significant factor contributing to growth.
Furthermore, in 2015, the Scottish Investment Bank and Chimaera Bio made investments in Sistemic Ltd. The collaborative funds amounting to USD 1.05 billion were used for the development of exosome products for stem cell assessment.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Exosomes Market Outlook will help companies and investors design strategic landscapes.
Kits & Reagents was the largest segment with a revenue share of 58.14% in 2024.
Horizon Databook has segmented the U.K. exosomes market based on kits & reagents, instruments, services covering the revenue growth of each sub-segment from 2018 to 2030.
In 2016, UK ranked the fifth largest global economy by GDP followed by Germany despite its exit from the EU. EvOx, a spin off from the University of Oxford, is involved in the development of a novel drug delivery method using exosomes.
Innovate UK granted USD 2.27 to Re Neuron Group plc to continue the development of its nanomedicine platform using exosomes. Collaborations among emerging players and research institutes is another significant factor contributing to growth.
Furthermore, in 2015, the Scottish Investment Bank and Chimaera Bio made investments in Sistemic Ltd. The collaborative funds amounting to USD 1.05 billion were used for the development of exosome products for stem cell assessment.
U.K. Exosomes Market Workflow Outlook (Revenue, USD Million , 2021-2033)
Isolation Methods
Downstream Analysis
U.K. Exosomes Market Product Outlook (Revenue, USD Million , 2021-2033)
Kits & Reagents
Instruments
Services
U.K. Exosomes Market End Use Outlook (Revenue, USD Million , 2021-2033)
Hospitals & diagnostics centers
Pharmaceutical & biotechnology companies
Academic & research institutes
U.K. Exosomes Market Application Outlook (Revenue, USD Million , 2021-2033)
Neurodegenerative diseases
Cardiovascular diseases
Others
Cancer
Infectious diseases
Reasons to subscribe to Exosomes Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Exosomes Market Outlook databook
Our clientele includes a mix of Exosomes Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.K. Exosomes Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.K. Exosomes Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.